1-8 of 8
Monika Wroclawska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Durable efficacy and long-term safety with pelabresib plus ruxolitinib in JAK Inhibitor–Naive myelofibrosis: 96-week Results from the Phase III MANIFEST-2 study

Free
Raajit Rampal, John Mascarenhas, Sebastian Grosicki, Dominik Chraniuk, Elisabetta Abruzzese, Prithviraj Bose, Aaron Gerds, Francesca Palandri, Vikas Gupta, Sung-Eun Lee, Alessandro Lucchesi, Andrew Kuykendall, Stephen Oh, Andrea Patriarca, alberto Alvarez-Larran, David Lavie, Moshe Talpaz, Jean-Jacques Kiladjian, Ruben Mesa, Monika Wroclawska, Xuechan Li, Thomas Lehmann, Harald Maier, Claire Harrison, Alessandro Vannucchi
Journal: Blood
Blood (2025) 146 (Supplement 1): 910.
https://doi.org/10.1182/blood-2025-910
Published: 2025
Journal Articles

Epik-P2: A Phase 2 Study of Alpelisib (ALP) in Pediatric and Adult Patients (pts) with PIK3CA -Related Overgrowth Spectrum (PROS)

Free
Guillaume Canaud, Juan Carlos López-Gutiérrez, Adrienne M Hammill, Lisa Weibel, Séverine Niglis, Michaela Paul, Athanasia Papadimitriou, Monika Wroclawska, Denise M Adams
Journal: Blood
Blood (2024) 144 (Supplement 1): 5512.
https://doi.org/10.1182/blood-2024-198497
Published: 2024
Journal Articles

U.S. Population Reference Values for the Myelofibrosis Symptom Assessment Form

Free
Robert Morlock, Andréa Martins Bayer, Amy Morlock, Monika Wroclawska, Chad Gwaltney
Journal: Blood
Blood (2024) 144 (Supplement 1): 2419.
https://doi.org/10.1182/blood-2024-210727
Published: 2024
Journal Articles

Adore: A Randomized, Open-Label, Phase 1/2 Open-Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Patients with Myelofibrosis

Free
Andrew Charles Perkins, MBBS,PhD, Kate Burbury, MBBS, FRACP, FRCPA, DPhil, Thomas Lehmann, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Andreas Reiter, MD, Vikas Gupta, MD FRCP, FRCPath, Claire Harrison, DM, FRCP, FRCPath, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Marielle Wondergem, MD, Robert Pack, PhD, Monika Wroclawska, MD, Celine Wilke, MD, Angela Zhang, PhD, Florian H. Heidel, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 52–53.
https://doi.org/10.1182/blood-2020-140408
Published: 2020
Journal Articles

The Final Analysis of Expand: A Phase 1b, Open-Label, Dose-Finding Study of Ruxolitinib (RUX) in Patients (pts) with Myelofibrosis (MF) and Low Platelet (PLT) Count (50 × 10 9 /L to < 100 × 10 9 /L) at Baseline

Free
Paola Guglielmelli, MD, Jean-Jacques Kiladjian, MD PhD, Alessandro M. Vannucchi, MD, Ming-hui Duan, MD, Haitao Meng, MD PhD, Ling Pan, MD PhD, Guangsheng He, MD PhD, Srdan Verstovsek, MD PhD, Françoise Boyer-Perrard, MD, Fiorenza Barraco, MD, Dietger Niederwieser, MD PhD, Anna Marina Liberati, MD, Claire Harrison, DM, FRCP, FRCPath, Pantelia Roussou, MSc, Monika Wroclawska, MD, Kevin Majidi, Peter AW te Boekhorst, MD PhD, Heinz Gisslinger, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-137742
Published: 2020
Journal Articles

Ruxolitinib for Patients (Pts) with Polycythemia Vera: Responders Vs Non-Responders As Defined in the Response Trial

Free
Srdan Verstovsek, MD PhD, Jean-Jacques Kiladjian, MD PhD, Monika Wroclawska, MD, Tuochuan Dong, Alessandro M. Vannucchi, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2947.
https://doi.org/10.1182/blood-2019-128101
Published: 2019
Journal Articles

Long-Term Efficacy and Safety (5 Years) in RESPONSE, a Phase 3 Study Comparing Ruxolitinib (rux) with Best Available Therapy (BAT) in Hydroxyurea (HU)-Resistant/Intolerant Patients (pts) with Polycythemia Vera (PV)

Free
Jean-Jacques Kiladjian, MD PhD, Pierre Zachée, Masayuki Hino, MDPhD, Fabrizio Pane, Tamas Masszi, MD Prof., Claire N. Harrison, MD DM, FRCP, PRCPath, Ruben A. Mesa, MD, Carole B. Miller, MD, Francesco Passamonti, MD, Simon Durrant, FRCP,FRCPath,MBBS, Martin Griesshammer, MD PhD, Keita Kirito, MD, Carles Besses, MD PhD, Beatriz Moiraghi, Elisa Rumi, MD, Vittorio Rosti, MD, Igor W. Blau, Nathalie Francillard, Tuochuan Dong, Monika Wroclawska, MD, Alessandro M. Vannucchi, MD, Srdan Verstovsek, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1753.
https://doi.org/10.1182/blood-2018-99-115129
Published: 2018
Journal Articles

Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,

Free
Jesús F. San-Miguel, MD, PhD, Vânia Tietsche de Moraes Hungria, MD, PhD, Sung-Soo Yoon, MD, PhD, Wieslaw Wiktor-Jedrzejczak, MD, PhD, Ashraf Elghandour, MD, Noppadol Siritanaratkul, MD, Meletios Athanasios Dimopoulos, MD, Paolo Corradini, MD, Thanyaphong Na Nakorn, MD, PhD, Tatiana Shelekhova, MD, Andreas Günther, MD, Kwee Yong, PhD, Robert Schlossman, MD, Monika Wroclawska-Swacha, MD, MBA, Hans-Jochen Weber, PhD, Priscille Bourquelot, MD, Jian Hou, MD, Hermann Einsele, MD, Jae Hoon Lee, MD, Philippe Moreau, MD, Sagar Lonial, MD, Paul G. Richardson, MD
Journal: Blood
Blood (2011) 118 (21): 3976.
https://doi.org/10.1182/blood.V118.21.3976.3976
Published: 2011